Keyphrases
Continuous Intravenous Infusion
100%
Cardiac Surgery
100%
Subcutaneous Administration
100%
Aprotinin
100%
Adult Patients
100%
Infusion Administration
100%
Nordic Countries
100%
Activity Level
100%
Randomized Clinical Trial
100%
EuroSCORE II
100%
High-risk Adults
100%
Coronary Artery Bypass Grafting
100%
Enoxaparin
100%
30-day Mortality
100%
Bypass Grafting
75%
Bolus
57%
Non-isolated
37%
Bolus Administration
28%
Patient Registry
25%
Aortic Dissection
25%
Patient Demographics
14%
Low Molecular Weight Heparin
14%
Randomized Controlled Clinical Trial
14%
Route of Administration
14%
Prospective Randomized Trial
14%
Activity Concentration
14%
Thromboprophylaxis
14%
Anti-Xa Level
14%
Trough Concentration
14%
Pharmacological Thromboprophylaxis
14%
Low Risk
14%
Bolus Injection
14%
Norway
12%
In-hospital Mortality
12%
Dialysis
12%
Registry Data
12%
Surgery Department
12%
Sweden
12%
Creatinine
12%
Anaphylactic Reaction
12%
Aortic Endocarditis
12%
Safety Profile
12%
High-risk Cardiac Surgery
12%
Resternotomy
12%
Safety Endpoints
12%
Finland
12%
Dual Antiplatelet Therapy
12%
Endocarditis
12%
Bleeding
12%
Adult Cardiac Surgery
12%
Pharmacology, Toxicology and Pharmaceutical Science
Enoxaparin
100%
Subcutaneous Injection
100%
Blood Clotting Factor 10
100%
Mortality Rate
100%
Randomized Clinical Trial
100%
Aprotinin
100%
Endocarditis
25%
Patient Registry
25%
Aortic Dissection
25%
Bleeding
12%
Anaphylaxis
12%
Creatinine
12%
Antiplatelet
12%
Hospital Mortality
12%
Thromboembolism
12%
Coronary Risk
10%
Bioavailability
10%
Controlled Clinical Trial
10%
Low Molecular Weight Heparin
10%
Medicine and Dentistry
Aprotinin
100%
Mortality Rate
100%
EuroSCORE
100%
Grafting
75%
Heart Surgery
37%
Aortic Dissection
25%
Patient Registry
25%
Endocarditis
25%
Anaphylaxis
12%
Thromboembolism
12%
Bleeding
12%
Median Sternotomy
12%
Antiplatelet
12%
Creatinine
12%
Hospital Mortality
12%
